Gil Blum
Needham & Company, LLC, Research Division

Good morning, everyone, and thank you for joining us at the second day of the Needham Healthcare Conference. My name is Gil Blum, and I'm a senior biotech analyst here at Needham & Company, and I cover the cell and gene therapy space. It is my pleasure to have with me today, Lynn Seely, the CEO of Lyell Biopharma or is it Immunopharma now?

Lynn Seely
Principal Executive Officer, President, CEO & Director

Immunopharma.

Gil Blum
Needham & Company, LLC, Research Division

Immunopharma, to discuss their very exciting programs, specifically in the CAR-T space. Very happy to have you here, Lynn. It's good to continue to see some efforts in this space despite certain investor sentiment. So maybe just starting with a broad overview of the company and its lead assets.

Lynn Seely
Principal Executive Officer, President, CEO & Director

Sure. Well, thank you, Gil, for inviting me. And yes, I think investor sentiment is clearly changing in the CAR T cell therapy space. For those of you who don't know Lyell, Lyell Immunopharma is a late clinical stage cell therapy company, really focused on bringing next-generation cell therapies to patients, both with hematologic malignancies as well as solid tumors.

And we have 2 programs in clinical development for large markets. The first is ronde-cel. This is a dual targeting CD19, CD20 CAR T cell therapy, which we have really designed to replace the CD19 CAR T cell therapies. We know this is an established $3 billion marketplace, but it needs better therapies. And ronde-cel has been very